Insider Trade: Fiduciary/Claymore MLP Opportunity Fund (FMO)’s director Ronald Toupin Bought 250 shares; Hutchin Hill Capital LP Cut Jazz Pharmaceuticals Plc (JAZZ) Holding By $881,050

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Hutchin Hill Capital Lp decreased Jazz Pharmaceuticals Plc (JAZZ) stake by 78.51% reported in 2017Q4 SEC filing. Hutchin Hill Capital Lp sold 6,575 shares as Jazz Pharmaceuticals Plc (JAZZ)’s stock rose 10.34%. The Hutchin Hill Capital Lp holds 1,800 shares with $242,000 value, down from 8,375 last quarter. Jazz Pharmaceuticals Plc now has $8.75B valuation. The stock decreased 3.08% or $4.645 during the last trading session, reaching $146.345. About 252,281 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 0.32% since April 2, 2017 and is downtrending. It has underperformed by 11.87% the S&P500.

The stock decreased 1.61% or $0.17 during the last trading session, reaching $10.39. About 194,663 shares traded. Fiduciary/Claymore MLP Opportunity Fund (NYSE:FMO) has declined 31.01% since April 2, 2017 and is downtrending. It has underperformed by 42.56% the S&P500.

Investors sentiment increased to 1.74 in 2017 Q4. Its up 0.36, from 1.38 in 2017Q3. It improved, as 6 investors sold Fiduciary/Claymore MLP Opportunity Fund shares while 13 reduced holdings. 20 funds opened positions while 13 raised stakes. 6.12 million shares or 7.99% more from 5.67 million shares in 2017Q3 were reported. Thomas J Herzfeld accumulated 1.23% or 251,066 shares. Bbva Compass Bankshares reported 81,210 shares stake. Moreover, Optimum Investment Advisors has 0.16% invested in Fiduciary/Claymore MLP Opportunity Fund (NYSE:FMO). Janney Montgomery Scott Lc reported 96,740 shares. Advsr Asset holds 486,803 shares or 0.11% of its portfolio. Bkd Wealth Advsr reported 16,240 shares stake. Walleye Trading Ltd Llc has invested 0% of its portfolio in Fiduciary/Claymore MLP Opportunity Fund (NYSE:FMO). Atlantic Tru Grp Ltd owns 27,015 shares. 50,712 were reported by Stifel Corp. Gemmer Asset Mgmt Ltd Liability Corporation invested in 0.01% or 1,300 shares. 910 are held by Hudock Gp Ltd Llc. Virtu Fincl Limited Liability Company holds 0.01% of its portfolio in Fiduciary/Claymore MLP Opportunity Fund (NYSE:FMO) for 11,343 shares. Raymond James Fincl Ser Advisors holds 0% in Fiduciary/Claymore MLP Opportunity Fund (NYSE:FMO) or 13,639 shares. Beese Fulmer Inv Management Incorporated holds 22,694 shares or 0.06% of its portfolio. Lpl Fincl Llc owns 15,652 shares.

Director, Ronald Toupin is the Fiduciaryclaymore Mlp Opportunity Fund’s insider which purchased shares of Fiduciaryclaymore Mlp Opportunity Fund, 250 to be exact. The reported shares were estimated based on $10.5, with Ronald Toupin’s investment valued at near $2,618 USD. Ronald Toupin now owns 3,054 shares or 0.01% of the company’s total market cap.

Fiduciary/Claymore MLP Opportunity Fund is a closed ended equity mutual fund launched and managed by Guggenheim Funds Investment Advisors, LLC. The company has market cap of $367.39 million. It is co-managed by Advisory Research, Inc. It has a 9.91 P/E ratio. The fund invests in the public equity markets of the United States.

Since December 14, 2017, it had 3 buys, and 0 sales for $154,515 activity. CUNNANE JAMES J JR bought 4,185 shares worth $50,588. Shares for $54,000 were bought by Barnes Randall C. Kiley Quinn Thomas also bought $49,927 worth of Fiduciary/Claymore MLP Opportunity Fund (NYSE:FMO) shares.

Analysts await Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report earnings on May, 8. They expect $2.30 earnings per share, up 63.12% or $0.89 from last year’s $1.41 per share. JAZZ’s profit will be $137.55 million for 15.91 P/E if the $2.30 EPS becomes a reality. After $2.58 actual earnings per share reported by Jazz Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -10.85% negative EPS growth.

Among 22 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 18 have Buy rating, 0 Sell and 4 Hold. Therefore 82% are positive. Jazz Pharmaceuticals had 78 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 24 by Stifel Nicolaus. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, September 19. The firm has “Buy” rating given on Tuesday, October 24 by BMO Capital Markets. The company was initiated on Friday, February 19 by Wells Fargo. Bernstein initiated Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Wednesday, November 25 with “Market Perform” rating. RBC Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Thursday, September 14 with “Buy” rating. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Friday, July 14 by Piper Jaffray. The company was initiated on Tuesday, January 2 by Leerink Swann. On Friday, October 9 the stock rating was initiated by Mizuho with “Buy”. As per Monday, July 17, the company rating was maintained by Deutsche Bank.

Since December 11, 2017, it had 0 buys, and 13 insider sales for $3.02 million activity. Treacy Paul also sold $122,446 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares. $1.26M worth of stock was sold by ENRIGHT PATRICK G on Monday, December 11. On Wednesday, February 14 the insider MILLER MICHAEL PATRICK sold $27,998. Young Matthew P. sold $163,998 worth of stock or 1,152 shares. COZADD BRUCE C sold $150,000 worth of stock or 1,000 shares.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart